 has granted fast-track approval to a new weight-loss pill developed by Eli Lilly){kind=link}
The Food and Drug Administration (FDA) has granted fast-track approval to a new weight-loss pill developed by Eli Lilly, marking a major milestone in the treatment of obesity.
The once-daily oral drug, known as orforglipron and marketed under the brand name Foundayo, is designed to help individuals manage obesity and related health conditions. It belongs to a class of medications called GLP-1 receptor agonists, which mimic a natural hormone that regulates appetite and promotes a feeling of fullness.
According to Eli Lilly, the drug is expected to be available as early as next week. Patients with insurance coverage may be able to access it for as little as $25 per month through discount programmes, while others could pay between $149 and $349 depending on dosage.
The approval comes amid increasing competition in the weight-loss drug segment, following a similar oral treatment introduced by Novo Nordisk.
The FDA reviewed Foundayo under an accelerated approval pathway, completing the process in just 50 days. Clinical trials involving over 3,000 adults showed promising results, with participants on the highest dose losing an average of 11.2% of their body weight over a 16-month period. In comparison, those given a placebo experienced only modest weight reduction.
Although the pill offers a more convenient alternative to injectable treatments, its effectiveness appears slightly lower than leading injectable drugs such as Zepbound and Wegovy.
However, researchers noted that patients taking the pill also saw improvements in key health indicators, including blood pressure and cholesterol levels.
Some trial participants reported side effects, primarily gastrointestinal issues, which led a small number to discontinue the treatment.
Experts believe the approval of Foundayo could significantly broaden access to obesity treatment, particularly for individuals who are unable to use or afford injectable medications, marking a new phase in the fight against obesity.